IFP Advisors’s Taysha Gene Therapies TSHA Stock Holding History

IFP Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$95	Hold	14	–	–	﹤0.01%	4963
2026 Q1	$63	Hold	14	–	–	﹤0.01%	4806
2025 Q4	$77	Hold	14	–	–	﹤0.01%	4646
2025 Q3	$46	Hold	14	–	–	﹤0.01%	4669
2025 Q2	$32	Buy	+14	New	+$30	﹤0.01%	4827

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IFP Advisors's TSHA Position: Q2 2026 in Review

IFP Advisors held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 14 shares worth $95. The position accounts for ﹤0.01% of the portfolio, ranked #4963.

IFP Advisors first reported a position in TSHA in Q2 2025 and has held it in 5 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

IFP Advisors held 14 shares of Taysha Gene Therapies worth $95 as of Q2 2026.
IFP Advisors left its Taysha Gene Therapies share count unchanged in Q2 2026.
Taysha Gene Therapies made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4963 holding.
IFP Advisors first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 5 quarters since.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.